In addition to genome-wide CNA, we evaluated the association between VEGFA amplification in cfDNA and treatment outcomes based on a previous study suggesting VEGFA genomic amplification in HCC tumor tissues as a predictive biomarker for sorafenib [6, 8]. Here, VEGFA is linked to hepatocellular carcinoma.